Core Viewpoint - The Anhui Provincial Science and Technology Department has announced the fourth batch of "Technology Vice Presidents," with 11 individuals appointed to technology-oriented enterprises in Anqing, covering various fields such as biomedicine, functional membrane materials, and ecological agriculture [1] Group 1 - The "Technology Vice President" initiative is a flexible talent introduction policy aimed at injecting innovation into enterprises by assigning research talents from universities and research institutions to serve as technical vice presidents [1] - This program has resulted in a total of 63 provincial-level "Technology Vice Presidents" currently serving in enterprises within Anqing [1] - The initiative aims to bridge the gap between industry, academia, and research, enhancing regional innovation efficiency and overall competitiveness, thus contributing to high-quality local development [1] Group 2 - Since the implementation of this policy, Anqing has established a regular selection process for provincial-level technology vice presidents, facilitating a green channel for technology personnel from universities to enter enterprises [1] - A dynamic scheduling mechanism has been set up to monitor the service status of "Technology Vice Presidents," including service duration, joint talent cultivation, platform construction, technical cooperation, and technology achievement transformation [1] - The program emphasizes proactive communication and service support to effectively leverage the innovative leadership role of "Technology Vice Presidents," accelerating the integration of innovation chains, industrial chains, and talent chains [1]

◎本报记者 代小佩 "唯有持续深化基础与转化研究融合，才能不断推动血液学科高质量发展，让更多血液疾病患者迎来治 愈希望，为全球血液学科发展贡献中国智慧与中国方案。"中国工程院院士、中国医学科学院血液病医 院（中国医学科学院血液学研究所）所院长、细胞生态海河实验室常务副主任程涛近日在第六届中国血 液学科发展大会上表示。 来源：科技日报 此外，单细胞时空多组学技术的应用，构建起中国大人群免疫细胞多组学队列，实现从基因到病理模型 的多模态数据融合，为精准诊疗提供支撑。统计数据显示，2020—2024年，我国血液病领域SCI论文总 数达25058篇，较上一个五年增长2.18倍，研究实力显著提升。 临床转化落地见效 血液学科基础研究突破正加速转化为临床实效。例如，张磊团队参与研发的血友病B基因治疗药物"信 玖凝"，成为亚洲首款无条件上市的基因治疗药物，为患者带来福音。中国医学科学院血液病医院（中 国医学科学院血液学研究所）副所院长施均介绍，地中海贫血基因治疗同样取得重大进展，慢病毒载体 与CRISPR-Cas9技术使90%以上患者实现临床治愈，相关研究有望于2026年进入二期临床试验。 与此同时，政策红利与协同机制为基 ...

Group 1 - AbbVie has secured a licensing agreement with Rongchang Biopharma worth up to $5.6 billion, which includes an upfront payment of $650 million and potential milestone payments of up to $4.95 billion [1] - The agreement grants AbbVie exclusive rights to develop, manufacture, and commercialize RC148, a bispecific antibody targeting PD-1 and VEGF, outside of Greater China [1] - RC148 is designed to enhance anti-tumor immune responses while inhibiting tumor-driven angiogenesis, and is currently undergoing clinical trials in China for various advanced malignancies [1] Group 2 - The PD-1/VEGF dual antibody market has seen increased interest, especially after Kangfang Biopharma's dual antibody demonstrated potential superiority over Merck's Keytruda in clinical trials [3] - Major pharmaceutical companies are investing in PD-1/VEGF dual antibodies, with significant licensing deals such as the $6.06 billion agreement between 3SBio and Pfizer, and the $11.1 billion collaboration between Bristol-Myers Squibb and BioNTech [3] - However, following disappointing overall survival data from Kangfang Biopharma's dual antibody, market enthusiasm for PD-1/VEGF dual antibodies has cooled, raising questions about the future potential of this therapeutic class [4] Group 3 - The recent licensing deal between Rongchang Biopharma and AbbVie may indicate a resurgence in interest in the PD-1/VEGF dual antibody space [4] - Kangfang Biopharma's partner, Summit, has submitted a new drug application to the FDA for its PD-1/VEGF dual antibody, targeting specific lung cancer patients, which could further influence market dynamics [4]

Market Overview - The Hong Kong stock market opened strongly on January 13, with the Hang Seng Index rising by 1.32%, the Hang Seng Tech Index increasing by 1.93%, and the China Enterprises Index up by 1.25% [1] - Notable gains were seen in tech stocks, with Alibaba rising nearly 5% and AI application stocks like Zhiyuan increasing by nearly 6%. The storage chip leader, Zhaoyi Innovation, saw its H-shares surge over 45% on its first trading day [1] Foreign Investment Outlook - According to Wind data, net inflows from southbound funds reached approximately HKD 32.694 billion, marking the highest weekly inflow in over a month and a half [2] - Major foreign institutions, including Goldman Sachs, Morgan Stanley, and UBS, have released positive market outlooks for 2026, driven by expectations of accelerated corporate profit growth, coordinated macro policies, and RMB appreciation [2] - The core drivers for the Chinese stock market's rise are shifting from "valuation recovery" in 2025 to "profit growth" in 2026, as per foreign institutions [2] Sector Recommendations - CITIC Securities suggests that the Hong Kong stock market could experience a second round of valuation recovery and performance revival in 2026, with a focus on sectors such as technology, healthcare, resources, consumer staples, paper, and aviation [2] - Western Securities highlights three factors driving the Hong Kong stock market's rebound: a weaker dollar encouraging international capital allocation to Hong Kong, RMB appreciation attracting Chinese capital back, and a recovery in the Chinese economy supported by inflation and potential debt relief policies [2] Market Sentiment and Trends - Huaxi Securities notes that the Hong Kong market has been underperforming compared to the A-share market, with a need for time to restore investor sentiment. The market has shown signs of recovery since late December, but the consensus for bullish sentiment remains to be solidified [3] - Huatai Securities indicates that the market sentiment index has entered a panic zone, historically leading to a significant increase in the probability of price rises in the following month [3] - ZheShang International maintains a cautious optimism regarding the market's mid-term outlook, despite a weak fundamental backdrop and a slight decline in the funding environment [3] Investment Opportunities - Industrial Securities recommends focusing on leading companies in the AI sector and dividend-paying assets in a low-interest-rate environment, including insurance, banking, energy, property management, and public utilities [4] - ZheShang International is optimistic about sectors benefiting from policy support, such as new energy, innovative pharmaceuticals, and AI technology, as well as low-valuation state-owned enterprises [4] - The 2026 spring performance of the Hong Kong market is expected to be driven by "AI applications, PPI improvement, and expanded domestic demand," with a focus on quality stocks in these areas [4] Company News - Rongchang Biopharmaceutical (09995) signed an exclusive licensing agreement with AbbVie for RC148, receiving an upfront payment of USD 650 million and potential milestone payments up to USD 4.95 billion [9] - WuXi AppTec (02359) forecasts a net profit of CNY 19.151 billion for 2025, representing a year-on-year increase of approximately 103% [9] - Dongfeng Motor Group (00489) reported cumulative vehicle sales of 1.8962 million units for 2025, a slight increase of 0.01% year-on-year [9] - Q Technology (01478) expects camera module sales to reach 45.938 million units for 2025, a year-on-year increase of 43.6% [9]

Core Viewpoint - The Liaoning Provincial Department of Industry and Information Technology has announced the second batch of advanced intelligent factories for 2025, with 35 enterprises selected, covering various sectors such as biomedicine, equipment manufacturing, electronic information, and new metallurgical materials. This brings the total number of advanced intelligent factories in the province to 273 [1] Group 1 - The selected enterprises include Shenyang Xingqi Eye Medicine and Dalian Zhongbi Power Battery among others [1] - The provincial government aims to implement a gradient construction action for intelligent factories, promoting the upgrade of production processes and management integration [1] - The goal for 2026 is to add over 80 advanced and above intelligent factories in the province [1] Group 2 - The initiative includes promoting basic-level intelligent factories, accelerating the transformation of production processes, and fostering collaborative management [1] - The plan also emphasizes the cultivation of excellent-level factories to drive multi-scenario intelligent applications [1] - The establishment of leading-level factories is aimed at innovating research paradigms, production methods, service systems, and organizational structures [1]

Core Viewpoint - Despite forecasting a net loss for 2025, the company shows signs of improving fundamentals through various operational and financial strategies aimed at enhancing financial health and long-term competitiveness [1][3]. Group 1: Financial Performance and Strategy - The company has reported positive revenue growth for two consecutive quarters and a net cash flow from operating activities that has been positive for three consecutive quarters, indicating improved operational quality [3]. - In January 2026, the company secured a syndicated loan of up to 10.2 billion yuan with a term of no more than three years, aimed at optimizing working capital and reducing debt repayment pressure [3]. - The company is also utilizing technology innovation bonds to further optimize its debt structure and mitigate associated risks [3]. Group 2: Research and Development - The company has 34 projects in the preventive biological products sector, with 24 entering clinical trials or application for market approval [6]. - Two self-developed influenza vaccines have been approved for market entry, with the quadrivalent influenza virus split vaccine already launched in 25 provinces [6]. - The company has made significant advancements in its pipeline, including the initiation of Phase III clinical trials for a dual-valent dysentery combined vaccine in Bangladesh, marking it as the first of its kind [6][7]. Group 3: Innovation and Talent Development - The company has invested over 6 billion yuan in R&D over the past three years, establishing a solid foundation for talent development, technological breakthroughs, and product innovation [8]. - A professional R&D team has been formed, including collaborations with top universities and research institutions, enhancing the company's innovation capabilities [10]. - The establishment of three major research and production bases in Beijing, Anhui, and Chongqing supports a comprehensive "prevention + treatment" development model [10]. Group 4: Global Expansion - The company is actively pursuing internationalization, conducting clinical trials for its products in various countries, including a Phase III trial for a dual-valent dysentery vaccine in Bangladesh [12]. - It has successfully supplied vaccines to countries like Indonesia and Nigeria, contributing to local epidemic prevention efforts [13]. - The company is enhancing its international presence by participating in global pharmaceutical exhibitions, thereby increasing the visibility of its products and technologies [13]. Group 5: Commitment to Innovation - The company emphasizes innovation-driven development, focusing on systemic innovation guided by clinical value and public health needs, aiming to transition from a follower to a leader in the biopharmaceutical industry [15].

Core Insights - Wuxi is experiencing significant economic growth, contributing 1.2% of China's GDP and 2.3% of A-share listed companies with a high-tech enterprise count nearing 8,000, ranking 10th nationally in innovation levels [1] - The integration of industry and finance is crucial for Wuxi's development, with a focus on deepening the collaboration between technological innovation and capital markets [1] Group 1: Capital Market Performance - In 2025, Wuxi added 8 new listed companies, raising a total of 7.374 billion yuan, ranking fifth nationally for new listings [2] - Over the "14th Five-Year Plan" period, Wuxi has seen a total of 56 new domestic and foreign listed companies, with 41 being domestic, bringing the total A-share companies to 127, surpassing three other higher GDP provincial cities [2] - Nearly 90% of new listings since 2020 are high-tech companies, with significant representation from integrated circuits, biomedicine, and high-end equipment manufacturing [2] Group 2: Mergers and Acquisitions - In 2025, Wuxi completed 57 mergers and acquisitions totaling 52.66 billion yuan, showcasing active corporate restructuring [3] - The establishment of large-scale funds, such as the 10 billion yuan Liangxi Science and Technology Mother Fund, has been pivotal in driving these mergers and acquisitions [3] Group 3: Financial Ecosystem Development - Wuxi's registered fund scale exceeded 600 billion yuan by October 2025, with 921 registered equity investment funds totaling over 550 billion yuan [3] - The establishment of the Shangxian Lake Fund Park has attracted over 370 equity investment firms, fostering a comprehensive financial service system [4] Group 4: Industrial Foundation and Innovation - Wuxi's modern industrial clusters are projected to reach a total scale of 18.8 trillion yuan by 2025, with over 2 billion yuan clusters increasing to eight [5] - The city emphasizes technology innovation, with a focus on integrating industry needs and supporting technology transfer [6][7] Group 5: Government Support and Policy Initiatives - The "Chuangtou Wuxi" initiative has organized 181 sessions over nine years, facilitating over 1,000 project roadshows and helping 161 projects secure 7.13 billion yuan in financing [7] - Wuxi has implemented various policies to support enterprise listings and enhance the capital market ecosystem, including the "Listing Pass" service platform [7] Group 6: Future Industrial Development - Wuxi is strategically investing in emerging industries such as artificial intelligence, commercial aerospace, and biomanufacturing, positioning itself at the forefront of the new technological revolution [8] - The city aims to enhance its capital market services and support the development of a more vibrant and regulated financial ecosystem [4][12]

Group 1 - The "China Optics Valley 3551 International Entrepreneurship Competition and Talent Fund 10th Anniversary Conference" was held in Wuhan, showcasing the achievements of the Optics Valley Talent Fund, which has invested in over 440 companies with a total fund size of 4.992 billion yuan, leveraging nearly 10 times social capital [1][2] - The "3551 Talent Plan" has attracted nearly 400 projects to settle in Optics Valley over the past 16 years, with the competition expanding its reach to global innovation hubs like Silicon Valley, London, and Tokyo, resulting in over 5,000 project entries [2][3] - The newly established Optics Valley Venture Capital Group aims to promote early-stage, small, long-term, and hard technology investments, creating a matrix-style "Optics Valley Capital" system to empower technological and industrial innovation [4] Group 2 - The conference saw the awarding of 11 sub-funds as "Optics Valley 3551 Talent Fund Partners," emphasizing investment in early-stage and hard technology ventures [3] - The Optics Valley region currently hosts 71 listed companies and over 5,800 high-tech enterprises, with a total of more than 167,000 companies, indicating a robust entrepreneurial ecosystem [4] - The establishment of 51 venture capital funds with a total scale of 12.1 billion yuan, including three seed funds of 250 million yuan each, reflects a strong commitment to supporting innovation and entrepreneurship [4]

责任编辑： 张家祺 近年来，我省完善优质中小企业梯度培育政策体系，加强差异化精准指导和常态化监测帮扶，分层级、 分产业建立专精特新企业培育库。 政策落地过程中，我省围绕财政、融资、创新、服务等关键环节协同发力。在财政支持方面，争取中央 财政资金5.6亿元、安排省级资金3.6亿元，支持专精特新"小巨人"企业打造新动能、攻坚新技术、开发 新产品、强化产业链配套能力。在融资促进方面，在全国率先推出"专精特新贷"业务，遴选57家金融机 构，累计发放信用类贷款395.15亿元，示范带动各类贷款投放2244.76亿元，为专精特新企业提供精准化 融资服务。在提升创新能力方面，组织大中小企业融通对接活动，开展大企业"发榜"中小企业"揭榜"工 作，引导企业攻克产业技术难题，提升中小企业的配套支撑能力。在公共服务供给方面，构建省、市、 县三级中小企业公共服务体系，融入全国中小企业服务"一张网"建设，围绕产业和企业发展需求，建设 服务平台矩阵，引导服务活动、服务资源向专精特新企业倾斜，持续擦亮"专精特新"金字招牌。（记者 陈辉） 1月12日，记者从省工业和信息化厅获悉，2025年全省新增专精特新"小巨人"企业54家、省级专精特新 ...

当前，世界百年未有之大变局加速演进，全球经济格局、产业布局、投资规则正在经历深刻调整，以人 工智能、绿色科技为代表的新质生产力加速崛起，既为双向投资合作带来了在新兴领域布局的全新机 遇，也对传统合作模式的转型升级提出了严峻挑战。最新发布的《中国双向投资报告2025》显示，2024 年中国双向投资结构持续优化、质量稳步提升。我国继续成为全球最具吸引力的投资目的地之一，作为 全球第三大外资流入国，对外直接投资流量和存量也连续多年稳居全球前三，这为江苏进一步深化双向 投资合作奠定了坚实基础、创造了有利环境。 江苏作为全国重要的经济大省、开放大省，始终处在对外开放的前沿，实际使用外资规模约占全国总量 的六分之一，连续多年保持全国第一，对外投资规模与质量也始终处于全国前列，形成了"引进 来"与"走出去"相互促进的良好态势。雄厚的产业基础、完善的供应链网络、活跃的创新资源和优越的 营商环境，构成了江苏拓展双向投资合作空间的综合优势。站在新的历史起点，江苏正肩负起在推进中 国式现代化中"走在前、做示范"的重大责任，要以双向投资合作的"广度"与"深度"为核心，着力打造具 有世界聚合力的双向开放枢纽。而紧紧依托国内大循环所驱动 ...